Table 1 Clinical and laboratory data pertaining to the 9 children with JDM who were treated with Rituximab
Patient ID | Gender | Race | MSA/MAA | Medication | Age range at 1st Ritux (yr) | No of Ritux doses | Disease Manifestations | Oligoclonal B cell expansion (CJ:KREC ratio) | B cell depletion (CJ:KREC ratio) | Response | Relapse |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | F | W | Ro ind, p155/140 + | CYC, IVIG, MTX, MMF, steroid | 10–14 | 5 | S + Mu | Yes (18.2) | Yes (1.5) | Yes | Yes |
2 | M | W | p155/140 + | CYC, IVIG, MTX, MMF, steroid | 10–14 | 2 | S + Mu | Yes (26.5) | Yes (1.5) | Yes | Yes |
3 | M | W | U1RNP + , MDA5 + , Ro + | MTX, MMF, HCQ, steroid | 10–14 | 1 | S only | Yes (8.5) | Yes (1.8) | Yes | No |
4 | F | H | p155/140 + | CYC, IVIG, MTX, MMF, HCQ, steroid | 15–18 | 1 | S only | Yes (18.3) | No (3.9) | No | n/a |
5 | F | W | p155/140 + | CYC, IVIG, MTX, MMF, HCQ, steroid | 10–14 | 1 | S + Mu | Yes (12.8) | Yes (2.4) | Yes | No |
6 | M | B | MJ + | CYC, MMF, HCQ, steroid | 15–18 | 2 | Mu only | Yes (8.7) | No (3.7) | Yes | Yes |
7 | F | W | p155/140 + | CYC, IVIG, MTX, MMF, HCQ, steroid | 10–14 | 1 | S + Mu | No (4.2) | Yes (1.9) | No | n/a |
8 | F | H | p155/140 + | CYC, IVIG, MTX, MMF, HCQ, steroid | 10–14 | 3 | S + Mu | No (3.5) | No (2.6) | No | n/a |
9 | F | W | p155/140 + | CYC, IVIG, MTX, MMF, HCQ, steroid | 15–18 | 4 | S only | No (6.1) | Yes (2.0) | No | n/a |